文献速递炎症性肠病

COVID-19与炎症性肠病中的免疫调节

COVID-19 and immunomodulation in IBD.
PubMed 文献 · Gut · 2020-04-17

本文综述COVID-19的病理生理,重点讨论免疫细胞激活,并探讨这些新认识对炎症性肠病免疫调节和生物治疗的潜在意义。文章提出IBD患者(如因肠道ACE2表达)是否更易感COVID-19及细胞因子释放综合征、免疫抑制是否影响COVID-19进展等关键问题。

要点

  • 需关注IBD患者是否因肠道ACE2表达而更易感COVID-19。
  • 免疫抑制是否影响COVID-19进展是当前重要问题。
  • COVID-19重症与高炎症和细胞因子风暴综合征相关。

核心结论

  • 本文综述COVID-19病理生理并讨论其对IBD免疫调节和生物治疗的潜在意义。

主要发现

  • COVID-19多数患者症状轻微或呈轻度流感样,但可导致进行性肺炎、急性呼吸窘迫综合征和器官衰竭等严重并发症。
  • 严重并发症由高炎症和细胞因子风暴综合征驱动。

临床怎么用

  • 在COVID-19大流行期间,需权衡IBD患者免疫抑制与免疫调节的处理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current coronavirus pandemic is an ongoing global health crisis due to COVID-19, caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to COVID-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of COVID-19. Here, the current understanding of the pathophysiology of COVID-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Neurath MF. COVID-19 and immunomodulation in IBD. Gut. 2020. PMID: 32303609. doi:10.1136/gutjnl-2020-321269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。